| human | Q5 |
| P496 | ORCID iD | 0000-0003-0828-0644 |
| P1053 | ResearcherID | D-5359-2017 |
| P108 | employer | Mayo Clinic | Q1130172 |
| P106 | occupation | researcher | Q1650915 |
| Q37524390 | A practical guide to the management of HCV infection following liver transplantation |
| Q92457800 | Applying Machine Learning in Liver Disease and Transplantation: A Comprehensive Review |
| Q98176422 | Association of α 1 Antitrypsin Phenotype and Development of Advanced Liver Disease and Pulmonary Complications Before and After Liver Transplantation |
| Q91332645 | Autoimmune hepatitis: Current and future therapeutic options |
| Q35094267 | Autoimmune hepatitis: a review of current diagnosis and treatment |
| Q38346716 | Bariatric surgery in patients with cirrhosis with and without portal hypertension: a single-center experience |
| Q26859216 | Burden of de novo malignancy in the liver transplant recipient |
| Q38424050 | Cardiovascular disease after liver transplantation: When, What, and Who Is at Risk |
| Q39116967 | Charcoal hemoperfusion in the treatment of medically refractory pruritus in cholestatic liver disease |
| Q91559316 | Circulating extracellular vesicles carrying sphingolipid cargo for the diagnosis and dynamic risk profiling of alcoholic hepatitis |
| Q88409452 | Cirrhotic Cardiomyopathy After Transplantation: Neither the Transient Nor Innocent Bystander |
| Q47632890 | Comparing Cardiopulmonary Exercise Testing in End-Stage Liver Disease Patients |
| Q50064497 | Cryptogenic Cirrhosis and Sitosterolemia: A Treatable Disease If Identified but Fatal If Missed |
| Q112277757 | DNA methylation profile of liver tissue in end-stage cholestatic liver disease |
| Q38812568 | De Novo Malignancies After Transplantation: Risk and Surveillance Strategies |
| Q91708901 | Diabetogenic Effects of Immunosuppression: An Integrative Analysis |
| Q91766106 | Differing Impact of Sarcopenia and Frailty in Nonalcoholic Steatohepatitis and Alcoholic Liver Disease |
| Q104481565 | Direct-Acting Antiviral Therapy in Liver Transplant Patients With Hepatocellular Carcinoma and Hepatitis C |
| Q89040796 | Editorial: transplantation in the setting of acute-on-chronic liver failure-calculating chances |
| Q97517614 | Enteric Dysbiosis in Liver and Kidney Transplant Recipients: A Systematic Review |
| Q38620054 | Everolimus is Associated With Less Weight Gain Than Tacrolimus 2 Years Following Liver Transplantation: Results of a Randomized Multicenter Study |
| Q38130193 | Extrahepatic implications of metabolic syndrome |
| Q48225055 | Fatty allograft and cardiovascular outcomes after liver transplantation |
| Q84692078 | Fatty liver and liver transplantation |
| Q48514721 | Feasibility and outcomes of percutaneous thermal ablation of hepatocellular carcinoma in a transplanted allograft |
| Q51442516 | Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. |
| Q36290635 | Frequency and prognosis of acute pancreatitis associated with fulminant or non-fulminant acute hepatitis A: A systematic review. |
| Q47707263 | Gender, Race and Disease Etiology Predict De Novo Malignancy Risk following Liver Transplantation: Insights for Future Individualized Cancer Screening Guidance |
| Q82585028 | Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients |
| Q38218762 | HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation |
| Q39066393 | Hepatocellular Carcinoma Is the Most Common Indication for Liver Transplantation and Placement on the Waitlist in the United States |
| Q93214587 | Hypothyroidism is associated with worse outcomes of hepatocellular carcinoma patients after liver transplantation |
| Q37982346 | Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation |
| Q41172899 | Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. |
| Q45357318 | Impact of sirolimus and tacrolimus on mortality and graft loss in liver transplant recipients with or without hepatitis C virus: an analysis of the Scientific Registry of Transplant Recipients Database |
| Q38962919 | Increasing Burden of Chronic Liver Disease Among Adolescents and Young Adults in the USA: A Silent Epidemic |
| Q37494953 | Interactions of allelic variance of PNPLA3 with nongenetic factors in predicting nonalcoholic steatohepatitis and nonhepatic complications of severe obesity |
| Q38137989 | Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review |
| Q94493022 | Intragastric Balloon Placement Induces Significant Metabolic and Histologic Improvement in Patients With Nonalcoholic Steatohepatitis |
| Q38528362 | Intrapulmonary vascular dilatations are common in portopulmonary hypertension and may be associated with decreased survival |
| Q47999211 | Investigation of PNPLA3 and IL28B genotypes on diabetes and obesity after liver transplantation: insight into mechanisms of disease |
| Q85939248 | Is 40 the new 30? |
| Q38605687 | Keys to long-term care of the liver transplant recipient |
| Q41222268 | Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease |
| Q91221292 | Letter to the editor |
| Q58559517 | Liver Transplantation Trends and Outcomes for Hereditary Hemorrhagic Telangiectasia In the United States |
| Q51798512 | Liver transplantation after share 35: Impact on pretransplant and posttransplant costs and mortality. |
| Q64898551 | Liver transplantation and nonalcoholic fatty liver disease. |
| Q37141352 | Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience |
| Q36399571 | Long-term medical management of the liver transplant recipient: what the primary care physician needs to know |
| Q49850570 | Long-term outcomes of patients undergoing simultaneous Liver Transplantation and Sleeve Gastrectomy. |
| Q92585175 | Long-term outcomes of the octogenarian donor liver recipient: The era of the new centurion |
| Q64895869 | Low Utility of Noninvasive Fibrosis Scores in Young Adults with Nonalcoholic Fatty Liver Disease. |
| Q91479538 | Low to Intermediate Dose Atropine Administration During Dobutamine Stress Echocardiography in the Pre-Liver Transplant Population |
| Q38533271 | Mammalian target of rapamycin inhibition after solid organ transplantation: can it, and does it, reduce cancer risk? |
| Q58549966 | Management of Recurrent and De Novo NAFLD/NASH after Liver Transplantation |
| Q51466759 | Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. |
| Q37901443 | Metabolic syndrome: is immunosuppression to blame? |
| Q36167215 | Mortality while awaiting liver retransplantation: predictability of MELD scores |
| Q91142453 | Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment |
| Q41461491 | Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant |
| Q41147723 | Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. |
| Q48337800 | NAFLD and Insulin Resistance Do Not Increase the Risk of Postoperative Complications Among Patients Undergoing Bariatric Surgery—A Prospective Analysis |
| Q88010964 | Natural History of Established and De Novo Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis |
| Q90313415 | New-Onset Diabetes and Preexisting Diabetes Are Associated With Comparable Reduction in Long-Term Survival After Liver Transplant: A Machine Learning Approach |
| Q45068803 | Nonalcoholic Steatohepatitis is the Most Rapidly Increasing Indication for Liver Transplantation in Young Adults in the United States |
| Q30238933 | Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic |
| Q36673799 | Nonalcoholic fatty liver: optimizing pretransplant selection and posttransplant care to maximize survival |
| Q45160087 | Nonalcoholic steatohepatitis in bariatric patients with a diagnosis of obstructive sleep apnea. |
| Q35802158 | Noninvasive diagnosis of acute cellular rejection in liver transplant recipients: a proteomic signature validated by enzyme-linked immunosorbent assay |
| Q37704369 | Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival |
| Q87177215 | Obesity evolution or revolution: there is more to it than meets the BMI |
| Q38272589 | Outcomes in liver transplantation: does sex matter? |
| Q112701866 | PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and 68 Ga-PSMA-11 PET Using Cyclotron-Produced 68 Ga |
| Q96435664 | Peripheral Endothelial Function as a Marker of Systemic Vasodilation in End-stage Liver Disease: Results of a Pilot Study |
| Q100527299 | Pharmacotherapy for Weight Loss in Cirrhosis and Liver Transplantation: Translating the Data and Underutilized Potential |
| Q99720966 | Pre-Existing Melanoma and Hematological Malignancies, Prognosis and Timing to Solid Organ Transplantation: A Consensus Expert Opinion Statement |
| Q99619288 | Pre-Transplant Solid Organ Malignancy and Organ Transplant Candidacy: A Consensus Expert Opinion Statement |
| Q35761385 | Prevalence and clinical consequences of Hepatitis E in patients who underwent liver transplantation for chronic Hepatitis C in the United States |
| Q36279632 | Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data |
| Q91026144 | Psychosocial Risk Impacts Mortality in Women After Liver Transplantation |
| Q93087176 | Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease |
| Q63256997 | Range of Normal Liver Stiffness and Factors Associated With Increased Stiffness Measurements in Apparently Healthy Individuals |
| Q42977335 | Recipient IL28B polymorphism is an important independent predictor of posttransplant diabetes mellitus in liver transplant patients with chronic hepatitis C. |
| Q47173917 | Recurrence of hepatocellular carcinoma: importance of mRECIST response to chemoembolization and tumor size. |
| Q89562249 | Recurrent or De Novo Allograft Steatosis and Long-term Outcomes After Liver Transplantation |
| Q92162938 | Redefining Cirrhotic Cardiomyopathy for the Modern Era |
| Q48232083 | Reducing the load: the evolution and management of obesity and nonalcoholic steatohepatitis before liver transplantation |
| Q88233369 | Reply |
| Q80974100 | Retransplantation for hepatitis C: results of a U.S. multicenter retransplant study |
| Q39278625 | Review article: maximising quality of life while aspiring for quantity of life in end-stage liver disease |
| Q43577357 | Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon. |
| Q100723732 | Role Of Symmetric Dimethylarginine In Predicting Future Renal Impairment In Liver Transplant Recipients |
| Q91605313 | Sarcopenia in Cirrhosis: Looking Beyond the Skeletal Muscle Loss to See the Systemic Disease |
| Q47990669 | Sarcopenia in hiding: The risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis |
| Q33812634 | Serum adipokine and inflammatory markers before and after liver transplantation in recipients with major cardiovascular events |
| Q90484346 | Sofosbuvir and Ribavirin Eradication of Refractory Hepatitis E in an Immunosuppressed Kidney Transplant Recipient |
| Q63256996 | Systematic review of acute pancreatitis associated with interferon-α or pegylated interferon-α: Possible or definitive causation? |
| Q40065699 | Systematic review of mixed cryoglobulinemia associated with hepatitis E virus infection: association or causation? |
| Q40059207 | Systematic review with meta-analysis: the association between hepatitis E seroprevalence and haemodialysis. |
| Q35863621 | The Intestinal Microbiome and the Liver Transplant Recipient: What We Know and What We Need to Know |
| Q39235812 | The Long Winding Road to Transplant: How Sarcopenia and Debility Impact Morbidity and Mortality on the Waitlist |
| Q84529488 | The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables |
| Q91325448 | The evolution and impact of sarcopenia pre- and post-liver transplantation |
| Q88254236 | The evolving role of the microbiome in liver failure and liver transplantation |
| Q51183032 | The impact of gender and NASH on chronic kidney disease before and after liver transplantation. |
| Q80757326 | The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database |
| Q50044688 | The reality of de novo malignancy: Sadly, not fake news |
| Q36480399 | The year in review--2004. |
| Q92108204 | Trasplante hepático y enfermedad hepática por hígado graso no alcohólico |
| Q98286823 | Ultrasound Attenuation Estimation in Harmonic Imaging for Robust Fatty Liver Detection |
| Q91193961 | Understanding and managing cardiovascular outcomes in liver transplant recipients |
| Q36967928 | Viral hepatitis in the Arctic. A review from a Circumpolar Workshop on Viral hepatitis, ICCH13. |
| Q90436689 | Women With Nonalcoholic Fatty Liver Disease Lose Protection Against Cardiovascular Disease: A Longitudinal Cohort Study |
Search more.